Comparative Pharmacology
Head-to-head clinical analysis: P A S SODIUM versus POTASSIUM AMINOSALICYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: P A S SODIUM versus POTASSIUM AMINOSALICYLATE.
P.A.S. SODIUM vs POTASSIUM AMINOSALICYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
P.A.S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
None Documented
None Documented
1 hour (normal renal function); prolonged to 5-7 hours in anuria or severe renal impairment; clinical context: requires frequent dosing or renal dose adjustment
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
Renal (80% as active drug and metabolites, primarily acetylated form); fecal (minor; <10%)
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent